+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-beta-Lactamase-Producing Escherichia coli

Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-beta-Lactamase-Producing Escherichia coli

We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended-spectrum-β-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of ≤2 mg/liter than for isolates with a higher MIC (0% versus 41.1%; P = 0.02).

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 036930257

Download citation: RISBibTeXText

Related references

Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrobial Agents and ChemoTherapy 57(7): 3402-3404, 2014

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clinical Microbiology and Infection 16(2): 132-136, 2010

Carbapenem versus Cefepime or Piperacillin-Tazobactam for the Empiric Treatment of Extended Spectrum β-lactamase Producing Escherichia coli Bacteremia in Patients with Hematologic Malignancy. Antimicrobial Agents and ChemoTherapy 2018, 2018

Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Journal of Infection 64(5): 533-534, 2012

Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (Esbl) prevalence cohort. Infection and Drug Resistance Volume 12: 1257-1264, 2019

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrobial Agents and ChemoTherapy 50(6): 2244-2247, 2006

In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli. Clinical Infectious Diseases 57(10): Iii-Iiv, 2014

Clinical outcome of patients with extended-spectrum beta-lactamase -producing Klebsiella pneumoniae and Escherichia coli bacteremia after treatment with expanded-spectrum cephalosporins. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 166, 1999

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. Bmc Infectious Diseases 17(1): 404, 2017

Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagnostic Microbiology and Infectious Disease 56(4): 351-357, 2006

Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum beta-Lactamase ESBL-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model Experimental Th. 2013

Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. International Journal of Antimicrobial Agents 49(4): 410-415, 2017

Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. International Journal of Infectious Diseases 17(2): E120-E124, 2013

Risk factors and outcome in extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Saudi Medical Journal 30(10): 1366-7; Author Reply1366-7, 2010

Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli. Journal of Infection and ChemoTherapy 24(11): 944-947, 2018